Gabapentinoids I have known and loved
New analysis shows gabapentinoids treat pain and anxiety by binding to α2δ proteins, not GABA receptors as originally thought.
A detailed technical analysis by user henryaj, posted on the AI and rationality forum LessWrong, has gone viral for demystifying the class of drugs known as gabapentinoids. The post clarifies that despite their name, drugs like gabapentin and pregabalin do not bind to GABA receptors. Instead, their therapeutic action comes from binding to the α2δ-1 subunit of voltage-gated calcium channels. This binding inhibits the calcium-triggered release of neurotransmitters like glutamate and substance P, particularly in 'sensitized' states such as neuronal injury, which explains their use for neuropathic pain, anxiety, and restless legs syndrome.
The analysis highlights key pharmacological differences. Structurally, gabapentinoids resemble amino acids leucine and isoleucine, which also bind α2δ, suggesting a natural ligand exists. A major practical distinction is absorption: gabapentin relies on the LAT1 amino acid transporter, leading to saturated uptake and multiple daily doses. In contrast, pregabalin uses additional transport mechanisms, avoids saturation, binds more strongly to α2δ, and demonstrates greater potency in animal models. The post also notes intriguing research linking the α2δ-1 protein to thrombospondin-mediated synapse formation, pointing to potential wider neurological impacts.
- Gabapentinoids like gabapentin work by binding to α2δ-1 proteins on calcium channels, not GABA receptors as their name implies.
- They inhibit neurotransmitter release in sensitized neural pathways, explaining efficacy for neuropathic pain and anxiety with minimal side effects.
- Pregabalin is pharmacologically superior, using multiple transporters for better absorption and binding more strongly to the α2δ target.
Why It Matters
Provides a clear mechanistic model for widely prescribed drugs, informing better clinical use and patient understanding.